Liver metastases

Research Reports

Effectiveness of Eribulin in Metastatic Breast Cancer Patients With Poor Prognostic Indicators in the United States

06/21/2021

A retrospective real-world study demonstrates the clinical effectiveness of eribulin in subgroups of MBC patients with poor prognostic characteristics, when used in accordance with the approved US indication.

A retrospective real-world study...

06/21/2021

Journal of Clinical Pathways

News

Can Y-90 Radioembolization Treat Metastases From Pancreatic Adenocarcinoma?

02/26/2019

Radioembolization with yttrium-90 (Y-90) microspheres may be an effective second-line therapy for patients with liver metastases from pancreatic adenocarcinoma, according to a study published in the Journal of Vascular and Interventional...

Radioembolization with...

02/26/2019

IO Learning

News

Upgrading Ablation, Targeting Technologies Minimizes Operator Dependency

12/16/2018

The introduction of computer assisted targeting solutions and efficient ablation modalities helped one high-volume center achieve excellent reproducible results as well as minimize operator dependency, according to an article published in the...

The introduction of computer...

12/16/2018

IO Learning

News

What’s the Impact of Hyperbilirubinemia on Future Liver Remnant Hypertrophy?

12/08/2018

At the time of percutaneous transhepatic portal vein embolization (PVE), hyperbilirubinemia has no apparent effect on future liver remnant (FLR) hypertrophy, according to a study published in the Journal of Vascular and Interventional...

At the time of percutaneous...

12/08/2018

IO Learning

News

Which Factors Affect Outcomes of Y90 Radioembolization in Heavily Pre-Treated Patients?

10/30/2018

A nomogram including 6 pre-Y90 radioembolization (RAE) parameters predicted overall survival (OS) post-RAE, according to a study published in Clinical Colorectal Cancer. A total of 103 patients with colorectal cancer liver metastases treated...

A nomogram including 6 pre-Y90...

10/30/2018

IO Learning

Liver Metastatic Disease: The Dangers of Data Misinterpretation

09/28/2017

In this Q&A, Daniel Sze, MD, PhD, discusses the results of SIRFLOX, FOXFIRE, and FOXFIRE Global trials and how continued investigations in this area, as well as in immunotherapy, may impact the field. Dr. Sze is a Professor of Radiology at...

In this Q&A, Daniel Sze, MD,...

09/28/2017

IO Learning

News

Surefire Receives Grant to Pursue Phase Ib Clinical Trial of CAR-T Immunotherapy Delivery Through Precision Infusion System

11/16/2016

WESTMINSTER, Colo., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Surefire Medical, Inc. announced a grant from the Colorado Office of Economic Development and International Trade (OEDIT) to initiate a Phase 1b immunotherapy clinical trial in...

WESTMINSTER, Colo., Nov. 15,...

11/16/2016

IO Learning

News

New SIRFLOX Analysis Shows Patients With Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumor Response to SIR-Spheres Y90 Resin Microspheres

07/08/2016

 Related: Selective Internal Radiation Therapy With Yttrium-90 Resin Microspheres in Metastatic Colorectal Carcinoma: The SIRFLOX StudyVideo interview: David Liu, MD, Discusses SIRFLOXSirtex Reports Preliminary SIRFLOX Study...

 Related: Selective...

07/08/2016

IO Learning

Clinical Insights

Transarterial Chemoembolization in Neuroendocrine Liver Metastasis

05/14/2014

Ricardo Garcia-Monaco , MD, PhD;

Andres Alejandro Kohan , MD;

Abstract: Neuroendocrine tumors (NET) are rare neoplasms that present in up to 40% of patients with metastasis at diagnosis, notably in the liver. Radical surgery is the treatment of choice, however it is seldom possible  in patients...

Abstract: Neuroendocrine tumors...

05/14/2014

IO Learning

Interview

The Best Interventional Oncology Therapy for the Patient

12/13/2013

By James G. Caridi, MD, FSIRIt is a well known fact that interventional radiology is the sin quo non for “there is more than one way to skin a cat.” This is epitomized in interventional oncology. We are inundated with a menu of options for...

By James G. Caridi, MD, FSIRIt...

12/13/2013

IO Learning